New approaches to triglyceride reduction: Is there any hope left?

Annalisa Filtz, Siddhant Parihar, Garred S. Greenberg, Christine M. Park, Andrea Scotti, Daniel Lorenzatti, Juan J. Badimon, Daniel E. Soffer, Peter P. Toth, Carl J. Lavie, Vera Bittner, Salim S. Virani, Leandro Slipczuk

Research output: Contribution to journalArticlepeer-review


Triglycerides play a crucial role in the efficient storage of energy in the body. Mild and moderate hypertriglyceridemia (HTG) is a heterogeneous disorder with significant association with atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and peripheral artery disease and represents an important component of the residual ASCVD risk in statin treated patients despite optimal low-density lipoprotein cholesterol reduction. Individuals with severe HTG (>1,000 mg/dL) rarely develop atherosclerosis but have an incremental incidence of acute pancreatitis with significant morbidity and mortality. HTG can occur from a combination of genetic (both mono and polygenic) and environmental factors including poor diet, low physical activity, obesity, medications, and diseases like insulin resistance and other endocrine pathologies. HTG represents a potential target for ASCVD risk and pancreatitis risk reduction, however data on ASCVD reduction by treating HTG is still lacking and HTG-associated acute pancreatitis occurs too rarely to effectively demonstrate treatment benefit. In this review, we address the key aspects of HTG pathophysiology and examine the mechanisms and background of current and emerging therapies in the management of HTG.

Original languageEnglish
Article number100648
JournalAmerican Journal of Preventive Cardiology
Publication statusPublished - Jun 2024


  • Atherosclerosis
  • Fibrates
  • Mortality
  • Omega-3
  • Statins
  • Triglycerides


Dive into the research topics of 'New approaches to triglyceride reduction: Is there any hope left?'. Together they form a unique fingerprint.

Cite this